Molecule Details
| InChIKey | VINPUJZJRCEBET-UHFFFAOYSA-N |
|---|---|
| Compound Name | 4-chloro-3,5-difluoro-N-[1-[2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]piperidin-4-yl]benzamide |
| Canonical SMILES | COc1ccc2nccc(CCN3CCC(NC(=O)c4cc(F)c(Cl)c(F)c4)CC3)c2n1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 5 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 6.71 |
| Source | ChEMBL |
2D Structure
Activity Profile
Target Activities (5)
| Target | Gene | Organism | Category | Pfam | pChEMBL | Type | Source |
|---|---|---|---|---|---|---|---|
| Q12809 | KCNH2 | Homo sapiens | Human | PF00027 PF00520 PF13426 | 6.8 | IC50 | ChEMBL |
| P0C1S7 | parE | Staphylococcus aureus | Pathogen | PF00204 PF00986 PF02518 PF01751 | 6.8 | IC50 | ChEMBL |
| P0C1U9 | parC | Staphylococcus aureus | Pathogen | PF03989 PF00521 | 6.8 | IC50 | ChEMBL |
| P0A0K8 | gyrB | Staphylococcus aureus | Pathogen | PF00204 PF00986 PF02518 PF01751 | 6.7 | IC50 | ChEMBL |
| P20831 | gyrA | Staphylococcus aureus | Pathogen | PF03989 PF00521 | 6.7 | IC50 | ChEMBL |